SightfileU.S. market data from official filings

TSCAN THERAPEUTICS INC (TCRX)

Name: TSCAN THERAPEUTICS INC (TCRX) — Institutional ownership, SEC filings and insider activity
Creator: Sightfile
License: https://www.sec.gov/privacy#dissemination

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001783328 · EDGAR filings · Updated 2026-06-22

TSCAN THERAPEUTICS INC (TCRX) has reported institutional ownership of 25.0%, with 60 institutional managers holding positions valued at $32.8M per the latest 13F reporting period.

Institutional ownership

25.0%

Institutional managers

Reported 13F value

$32.8M

Insider activity

5 trans.

$3.25M net buying

Latest updates

2026-06-22 — Current report (8-K) filed
2026-05-22 — Insider transaction reported (Form 4)
2026-05-22 — Current report (8-K) filed
2026-05-22 — Insider transaction reported (Form 4)
2026-05-22 — Insider transaction reported (Form 4)
2026-05-22 — Insider transaction reported (Form 4)

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, TSCAN THERAPEUTICS INC has 60 institutional holders and institutional ownership of 25.0%.

Insider activity

Insiders reported 5 transactions (5 buys, 0 sells) across 1 reporting insiders, with a net reported value of $3.25M.

Related companies

NUVECTIS PHARMA INC (NVCT) · FRACTYL HEALTH INC (GUTS) · CHAMPIONS ONCOLOGY (CSBR) · LIFEVANTAGE CORP (LFVN) · CELLECTIS S A (CLLS) · CONNECT BIOPHARMA HLDGS LTD (CNTB)

See full history, cross-references and alerts on Sightfile

Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-06-22.